Navarro-Triviño, Francisco JoséLozano-Lozano, MarioRuiz-Villaverde, Ricardo2025-01-072025-01-072021-05-202160-9381https://hdl.handle.net/10668/26016Psoriasis is a chronic inflammatory disease that has a negative impact on patients' quality of life. Patients with mild-moderate psoriasis can be treated with topical medications, such as the combination drug calcipotriol/betamethasone dipropionate (Cal/BD). This study investigated the adherence of psoriasis patients to therapy with Cal/BD aerosol foam, as well as their satisfaction with the treatment's efficacy, safety, and effect on their quality of life. Patients with mild-moderate plaque psoriasis were eligible to participate in this open-label, non-placebo controlled, prospective single-center study. Adherence to treatment was assessed using the Morisky-Green scale 4 and 12 weeks after the start of treatment. Satisfaction with the treatment was assessed using the abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9). The severity of psoriasis was assessed on the mIGA and PGA scales, and the impact on quality of life was assessed using the PDI and DLQI scales. A total of 65 patients entered the study. Adherence to treatment was good, with 73.8% of patients showing high adherence at 12 weeks. Satisfaction was also good, with 46 patients (70.8%) being completely satisfied. Over a 4-week period, patients treated with Cal/BD aerosol foam had significant improvement in disease severity that was directly related to treatment adherence.enAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/adherence, satisfaction, calcipotriolbetamethasone, aerosol foam, psoriasisresearch article34123560open access10.5826/dpc.1103a56PMC8172017https://www.dpcj.org/index.php/dpc/article/download/dermatol-pract-concept-articleid-dp1103a56/dpc1103a56-pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC8172017/pdf